Loading
Led the first personalised neoantigen peptide vaccine trial in melanoma and mapped how CLL evolves under treatment.
Catherine Wu led the 2017 Nature trial of NeoVax, a personalised neoantigen peptide vaccine that induced durable T-cell responses in melanoma patients, published alongside Şahin's mRNA work as the founding evidence for individualised cancer vaccines. Her laboratory also defined the clonal evolution of chronic lymphocytic leukaemia and its driver mutations. She directs transplantation and cellular therapies at Dana-Farber.
Shares Dana-Farber Brigham Cancer Center, Whole-exome & whole-genome sequencing and the tag genomics.
Shares Dana-Farber Brigham Cancer Center, Glioma & glioblastoma.
Shares Personalised neoantigen (mRNA) vaccines, Melanoma and the tag genomics.
Shares Broad Institute of MIT and Harvard, Glioma & glioblastoma.
Shares Personalised neoantigen (mRNA) vaccines, Glioma & glioblastoma, Melanoma.
Shares Broad Institute of MIT and Harvard, Whole-exome & whole-genome sequencing.
Shares Broad Institute of MIT and Harvard, Dana-Farber Brigham Cancer Center.
Shares Personalised neoantigen (mRNA) vaccines, Melanoma and the tag vaccine.